Viking Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Brian Lian
- Full Time Employees
- 65
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 9920 Pacific Heights Boulevard San Diego CA United States of America 92121
- IPO Date
- Apr 28, 2015
- CIK
- 0001607678
- Website
- vikingtherapeutics.com
- Similar Companies
- Business
- Viking Therapeutics, Inc. (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for metabolic and endocrine disorders. Founded in 2012 and headquartered in San Diego, California, the company advances a pipeline targeting obesity, metabolic dysfunction-associated steatohepatitis (MASH), non-alcoholic fatty liver disease (NAFLD), lipid disorders, and rare diseases such as X-linked adrenoleukodystrophy (X-ALD). Its core programs include VK2735, a dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist available in subcutaneous and oral formulations for obesity and related metabolic conditions; VK2809, an orally available small molecule selective thyroid hormone receptor beta (TR beta) agonist for MASH, fibrosis, NAFLD, and elevated low-density lipoprotein cholesterol (LDL-C); dual amylin and calcitonin receptor agonists (DACRAs) for obesity; and VK0214, an orally available selective TR beta agonist for X-ALD. Viking Therapeutics operates primarily in the United States with a focus on patients suffering from high unmet needs in metabolic and endocrine diseases, leveraging internal expertise in metabolism to drive innovation across its wholly-owned pipeline. The company's lead candidate, subcutaneous VK2735, advances in Phase 3 VANQUISH-1 and VANQUISH-2 registration trials for obesity in adults with and without type 2 diabetes, following positive Phase 2 VENTURE trial results; the oral formulation of VK2735 progresses in the Phase 2 VENTURE-Oral trial, with enrollment completed and data anticipated in the second half of 2025. VK2809 met primary and secondary endpoints in the Phase 2b VOYAGE trial for biopsy-confirmed MASH and fibrosis, building on prior Phase 2a data showing significant LDL-C and liver fat reductions; VK0214 demonstrated proof-of-concept in a Phase 1b trial for X-ALD by reducing very long-chain fatty acids. Recent developments include the completion of enrollment in the Phase 3 VANQUISH-1 trial for subcutaneous VK2735 in November 2025, alongside plans for a Phase 1 monthly dosing study in the third or fourth quarter of 2025 and an investigational new drug (IND) filing for its amylin agonist program in the fourth quarter of 2025. In March 2025, Viking secured a $150 million multi-year manufacturing agreement with CordenPharma to produce multiple metric tonnes of VK2735 annually, supporting over one billion oral pills or substantial injectable volumes to meet potential commercial demand. Phase 3 trials for subcutaneous VK2735 commenced in the second quarter of 2025, positioning the company to compete in the expanding obesity market dominated by GLP-1-based therapies.
Company News
Viking Therapeutics (VKTX) Delivers Great VK2735 Results: Here's a Word of Caution
3 Numbers From Viking Therapeutics' Weight-Loss Drug Trial That Have Wall Street Buzzing
Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Why Is Viking Therapeutics Stock Trading Down Thursday?
Here's Why Viking Therapeutics Shares Slumped Today
Viking Therapeutics Sinks 15% After Pricing Upsized $500M Offering; Jaguar Health Tumbles 25%
Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes
Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Know
QUICK SPARK: Viking Therapeutics Stock Gains 40% in 2 Days
Viking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes
Viking's Obesity Edge May Be Staying Power, Not Weight Loss
Viking Therapeutics: 'Strong Buy' On Injectable VK2735 Maintenance Data And Treatment Optionality
Two Biotechs Get Beaten Down: Jaguar Health Collapses 59%, Viking Therapeutics Sinks 4%
VKTX Stock Rises on Encouraging Weight-Loss Maintenance Results
Breakfast News: A Warning Shot for Housing?
Viking Therapeutics’ VK2735 Shows Strong Weight-Loss Retention With Monthly Dosing
Why Viking Therapeutics Stock Skyrocketed on Tuesday
Viking Therapeutics, Inc. (VKTX) Discusses Top Line Data from VK2735 Maintenance Study in Obesity and Type 2 Diabetes Transcript
Nasdaq 100 Flirts with Records, Oil Sinks for Fifth Day: Stock Market Today